Table 4.

Efficacy of sorafenib with HAIC using Low-dose FP

No. of patients	Cohort 1 Sorafenib 400 mg twice daily CDDP 14 mg/m2 5-FU 170 mg/m2 (n=6)	Cohort 2 Sorafenib 400 mg twice daily CDDP 14 mg/m2 5-FU 330 mg/m2 (n=6)	Cohort 3 Sorafenib 400 mg twice daily CDDP 20 mg/m2 5-FU 330 mg/m2 (n=6)	Total (n=18)
Best overall tumor response
CR	0	0	0	0
PR	3	1	3	7
SD	1	4	2	7
PD	0	1	1	2
NE	2	0	0	2
Objective response rate (CR + PR),%	50	16.7	50	38.9
Disease control rate (CR + PR + SD),%	66.7	83.3	83.3	77.8

NE=not evaluable.